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Adjuvants  are  increasingly  used  by the vaccine  research  and  development  community,  particularly  for
their  ability  to enhance  immune  responses  and  for their  dose-sparing  properties.  However,  they  are  not
readily  available  to  the  majority  of public  sector  vaccine  research  groups,  and  even those  with  access  to
suitable  adjuvants  may  still fail  in  the  development  of their  vaccines  because  of  lack  of  knowledge  on  how
to  correctly  formulate  the  adjuvants.  This  shortcoming  led  the  World  Health  Organization  to  advocate  foril-in-water emulsion the  establishment  of  the  Vaccine  Formulation  Laboratory  at  the  University  of  Lausanne,  Switzerland.  The
primary  mission  of the  laboratory  is to transfer  adjuvants  and  formulation  technology  free of  intellec-
tual  property  rights  to academic  institutions,  small  biotechnology  companies  and  developing  countries
vaccine  manufacturers.  In  this  context,  the  transfer  of an  oil-in-water  emulsion  to  Bio  Farma,  an  Indone-
sian  vaccine  manufacturer,  was  initiated  to  increase  domestic  pandemic  inﬂuenza  vaccine  production
capacity  as  part of  the  national  pandemic  inﬂuenza  preparedness  plan.. Introduction
With the exception of aluminium salts, adjuvants that can be
sed in prophylactic vaccination have mostly been developed by
 few large vaccine manufacturers. Gaining access to these adju-
ant systems has been challenging for academic researchers, small
iotechnology companies and developing countries vaccine manu-
acturers (DCVMs). Even for adjuvants free of intellectual property
arriers, expertise on how to select, use and characterize appro-
riate adjuvant systems remains scarce and is in the hands of a
mall number of industry experts. To facilitate access to adjuvants,
he Vaccine Formulation Laboratory was established in January
010 at the University of Lausanne (UNIL), Switzerland, under the
uspices of the World Health Organization (WHO). This initiative
omplements the creation in 2007 of a centre dedicated to the
esearch and development of adjuvants at the Infectious Disease
esearch Institute in Seattle, United States of America. The Vac-
ine Formulation Laboratory is hosted by the UNIL Department of
iochemistry, a WHO  collaborating centre on immunology, and
rings together adjuvant and formulation experts. The Vaccine
ormulation Laboratory’s mandate is to act as a platform for the
ransfer of adjuvant technology (with a focus on mature tech-
ologies such as aluminium salts and oil-in-water emulsions), to
rovide access to adjuvant systems including generic formulations,
ommercially available adjuvants and proprietary adjuvants pro-
ided under material transfer agreements, and to support adjuvant
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users through training and custom vaccine formulation services. In
addition, the laboratory is involved in the harmonization of meth-
ods to evaluate adjuvants. The primary recipients of these services
are public sector institutions, small biotechnology companies and
DCVMs.
2. Application of the adjuvant technology transfer platform
to the formulation of pandemic inﬂuenza vaccines
In  June 2010, the United States Department of Health and
Human Services’ Biomedical Advanced Research and Development
Authority (US HHS BARDA) announced a funding opportunity enti-
tled “Development and Sustainable Manufacturing of Adjuvanted
Pandemic Inﬂuenza Vaccines in Developing Countries”. This was
part of a set of grants aimed at increasing access to effective vaccines
in developing countries at the onset of a potential pandemic. Recent
forecasts, as well as experience from the 2009 (H1N1) pandemic,
indicate that current inﬂuenza vaccine production capacity remains
insufﬁcient to allow the global surge capacity needed within the
timeframe of an emergency response [1,2]. In October 2010, US HHS
BARDA selected the Vaccine Formulation Laboratory to transfer
technology for the production and characterization of an oil-in-
water emulsion for adjuvantation of pandemic inﬂuenza vaccines
in Indonesia [3].
Open access under CC BY-NC-ND license.2.1.  Selection of adjuvant technology
The choice of oil-in-water emulsions for pandemic inﬂuenza
vaccine adjuvantation was based on several factors.
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Firstly, the licensed oil-in-water adjuvants AS03 (GlaxoSmithK-
ine (GSK)) and MF59 (Novartis), as well as AF03 (Sanoﬁ Pasteur)
ave demonstrated remarkable antigen-sparing capacity (i.e. a
eduction in the amount of antigen required per vaccine dose) for
andemic inﬂuenza vaccines. For H5N1 inﬂuenza vaccines based
n split or subunit antigens, two doses of 90 g (haemagglutinin
HA) content) are normally required to induce an immune response
hat meets registration criteria. Although adjuvantation with alu-
inium salts allows moderate antigen-sparing, the formulation
f pandemic inﬂuenza vaccines with oil-in-water emulsions can
chieve immunity with as low as 3.5–7.5 g per vaccine dose [4,5].
herefore, the antigen-sparing properties of oil-in-water adjuvants
ermit signiﬁcant enhancement of existing production capacity in
he event of a pandemic. Manufacturing facilities producing sea-
onal vaccine for a small domestic market could rapidly scale up
roduction capacity by formulating reduced amounts of vaccine
ntigen with an oil-in-water adjuvant.
Secondly, oil-in-water emulsions improve vaccine responses
gainst seasonal inﬂuenza in elderly populations, immunocom-
romised patients and children [6]. They can also broaden the
mmunogenicity of pandemic vaccines as shown by the MF59-
nduced epitope spreading from HA2 to neuraminidase and HA1,
hus providing cross-clade neutralization and potentially improv-
ng in vivo protection [7].
Thirdly,  the safety proﬁle of oil-in-water emulsions is well doc-
mented: MF59 and AS03 have been used successfully in over
00 million people including children. Novartis’ seasonal inﬂuenza
accine containing MF59 is routinely and extensively used in the
lderly [8], and both GSK’s AS03-adjuvanted pandemic (H1N1)
009 inﬂuenza vaccine and Novartis’ MF59-adjuvanted pandemic
H1N1) 2009 inﬂuenza vaccine were used worldwide in 2009 and
010.
It is worth noting that the technology transfer of an emulsion
ontaining metabolizable oil and surfactant in the absence of block-
opolymer from a European centre to DCVMs does not infringe any
ntellectual property. Access by DCVMs to this adjuvant technol-
gy would therefore be highly advantageous not only for pandemic
nﬂuenza vaccines, but could trigger beneﬁts for further applica-
ions since oil-in-water emulsions have been widely investigated
n numerous clinical trials with several subunit antigens, such as
IV, hepatitis B virus and hepatitis C virus antigens [9]. In addition,
he capital investment needed to produce oil-in-water adjuvants is
elatively modest and the cost of materials adds only marginally to
he cost of antigen production.
.2.  Development of processes
The  manufacturing process for oil-in-water emulsions has been
escribed in detail [10]. The Vaccine Formulation Laboratory has
stablished the production processes and prepared oil-in-water
mulsions that meet all expected physical, chemical and biolog-
cal (adjuvant activity) parameters. We  are currently screening a
ange of raw material sources and evaluating the acceptability of
he products for use in clinical-grade emulsions. This is particu-
arly important for materials of biological origin such as squalene
prepared from shark liver) and heterogeneous surfactants such as
ween80 and Span85. In order to develop all standard operating
rocedures and relevant documentation for Good Manufacturing
ractice (GMP) production, a collaboration has been developed
ith The Netherlands Vaccine Institute (NVI) in Bilthoven, The
etherlands.. Operationalization of the adjuvant hub
Bio Farma, Indonesia, a grantee of the WHO  initiative to trans-
er the capacity to produce inﬂuenza vaccines to DCVMs, is the
rst technology transfer partner of the Vaccine Formulation Lab-e 29S (2011) A37– A39
oratory.  The ﬁrst phase of the project comprises the installation of
equipment required for production and characterization of oil-in-
water emulsions, the establishment of relevant standard operating
procedures, training of laboratory staff, and on-site validation of
the transferred processes. Once production of the oil-in-water
emulsion is established locally, preclinical studies compliant with
national regulatory requirements will be conducted prior to human
clinical testing of oil-in-water adjuvanted pandemic inﬂuenza vac-
cines.
4. Provision of adjuvants, support for vaccine formulation
and  training
The  Vaccine Formulation Laboratory is facilitating access to
adjuvants that are either not covered by intellectual property rights
or can be made readily available under licence agreements, and is
providing support for vaccine formulation. This activity was initi-
ated as a part of TRANSVAC, a collaborative infrastructure project
funded under the European Commission’s Seventh Framework Pro-
gramme. The laboratory will also provide practical training courses
on vaccine formulation, the ﬁrst of which is scheduled for 2012.
5.  Harmonization platform for adjuvant comparison
One challenge in the ﬁeld of vaccine adjuvants is the lack of
comparative data that would facilitate their preclinical selection.
The Vaccine Formulation Laboratory is engaged in the develop-
ment of an immunological read-out methodology for harmonized
adjuvant evaluation and down-selection by collaborating in the
PHARVAT project with the Biomedical Primate Research Center
(Rijswijk, The Netherlands), the European Vaccine Initiative (Hei-
delberg, Germany) and WHO. The results from this project will be
published and adjuvants, antigens, reference sera and the immu-
nization protocol will be made available to allow adjuvant and
vaccine developers to test their products in direct comparison with
PHARVAT’s reference materials.
6. Concluding remarks and prospects
Adjuvants are increasingly being used in modern vaccinology.
However, aside from aluminium salts, which have been in use since
the 1920s, very few adjuvant technologies are readily accessible
to the public sector, small biotechnology companies or DCVMs.
Although this situation is evolving, as several vaccine adjuvant
systems are now (or soon will be) in the public domain, access
to adjuvants is only of value if accompanied by access to vaccine
formulation know-how. The establishment of a platform to trans-
fer adjuvant technology and formulation expertise to public sector
vaccine developers and DCVMs addresses these needs. As demon-
strated by the success of the International Technology Platform for
Inﬂuenza Vaccines at NVI, a centralized hub with speciﬁc pilot-
plant material and hands-on training courses is sustainable when
there is demand for the technology. Several DCVMs have already
indicated interest in acquiring the adjuvant technology developed
at the Vaccine Formulation Laboratory for their pandemic inﬂuenza
preparedness plans. The oil-in-water technology will be transferred
to new beneﬁciaries and programmes targeting other diseases are
also being considered.
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